Overview

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The study compares 2 medicines for children who do not have enough hormone to grow: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe). Researchers will test to see how well somapacitan works. The study will also test if somapacitan is safe. Participants will either get somapacitan or Norditropin® - which treatment participants get, is decided by chance. The study includes a 52 week treatment period and a minimum of 30 days follow up period.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S